Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RB1 | P06400 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038238 | 0.92 | HTR6 (0.49) | HTR6MAPTTP53LMNAPOLB | |
| SCHEMBL6038306 | 0.91 | HTR6 (0.54) | HTR6MAPTTP53LMNAPOLB | |
| SCHEMBL6038302 | 0.90 | HTR6 (0.60) | HTR6MAPTTP53LMNAPOLB | |
| SCHEMBL26836966 | 0.84 | HTR2A (0.55) | HTR6HTR2CHTR2BHTR2AMAPKAPK2 | |
| SCHEMBL6038290 | 0.83 | HTR6 (0.52) | HTR6MAPTTP53LMNAPOLB | |
| SCHEMBL6038307 | 0.82 | HTR2C (0.56) | HTR6MAPTTP53LMNAPOLB | |
| SCHEMBL6038282 | 0.81 | HTR6 (0.67) | HTR6MAPTTP53LMNAPOLB | |
| SCHEMBL6038284 | 0.77 | HTR2C (0.50) | HTR6HTR2CHTR2BHTR2AMAPKAPK2 | |
| SCHEMBL6038336 | 0.76 | HTR6 (0.58) | HTR6 | |
| SCHEMBL26836953 | 0.75 | RB1 (0.55) | MAPTLMNARB1HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1196417-B8 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1196417-B1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | UPJOHN CO (US) | 2005-04-20 | — | — | EP | claimed |
| US-20020156275-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA AND UPJOHN COMPANY | 2002-10-24 | — | — | US | claimed |
| US-20020128475-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| US-20020111483-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY | 2002-08-15 | — | — | US | claimed |
| EP-1196417-A1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN COMPANY (US) | 2002-04-17 | — | — | EP | claimed |
| WO-2001005793-A1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| US-7030109-B2 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| US-6921823-B2 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1196417-B8 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1196417-B1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | UPJOHN CO (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6878823-B2 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040248880-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-B]indoles containing arylsulfones at the 9-position | JACOBSEN ERIC JON (US) | 2004-12-09 | — | — | US | disclosed |
| US-20040054170-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | JACOBSEN ERIC JON (US) | 2004-03-18 | — | — | US | disclosed |
| US-20020156275-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA AND UPJOHN COMPANY | 2002-10-24 | — | — | US | disclosed |
| US-6468999-B1 | TREATING ANXIETY, DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS IN HUMANS AND ANIMALS | PHARMACIA & UPJOHN COMPANY | 2002-10-22 | — | — | US | disclosed |
| US-20020128475-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | disclosed |
| US-20020111483-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | PHARMACIA & UPJOHN COMPANY | 2002-08-15 | — | — | US | disclosed |
| EP-1196417-A1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN COMPANY (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005793-A1 | 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION | PHARMACIA & UPJOHN COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111483-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | HTR4, HTR3C, HTR3B | HTR6 16/4885MAPT 4204/4885TP53 4882/4885 |
| US-20040248880-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-B]indoles containing arylsulfones at the 9-position | TPH1, HTR1A, HTR1D | HTR6 19/4885MAPT 4660/4885TP53 4879/4885 |
| US-20040054170-A1 | 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | TPH1, HTR1A, HTR1D | HTR6 19/4885MAPT 4660/4885TP53 4879/4885 |
| US-20020156275-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | HTR4, HTR3C, HTR3B | HTR6 16/4885MAPT 4204/4885TP53 4882/4885 |
| US-20020128475-A1 | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | HTR4, HTR3C, HTR3B | HTR6 17/4885MAPT 4344/4885TP53 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.